7AJR | pdb_00007ajr

Virtual screening approach leading to the identification of a novel and tractable series of Pseudomonas aeruginosa elastase inhibitors

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free: 
    0.240 (Depositor), 0.240 (DCC) 
  • R-Value Work: 
    0.208 (Depositor), 0.208 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 7AJR

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history. 

Literature

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors.

Leiris, S., Davies, D.T., Sprynski, N., Castandet, J., Beyria, L., Bodnarchuk, M.S., Sutton, J.M., Mullins, T.M.G., Jones, M.W., Forrest, A.K., Pallin, T.D., Karunakar, P., Martha, S.K., Parusharamulu, B., Ramula, R., Kotha, V., Pottabathini, N., Pothukanuri, S., Lemonnier, M., Everett, M.

(2021) ACS Med Chem Lett 12: 217-227

  • DOI: https://doi.org/10.1021/acsmedchemlett.0c00554
  • Primary Citation Related Structures: 
    7AJR

  • PubMed Abstract: 

    Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa , which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 ( K i = 0.16 μM and 0.12 μM, respectively).

    • Organizational Affiliation: 
    • Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Macromolecule Content 

  • Total Structure Weight: 33.7 kDa 
  • Atom Count: 2,468 
  • Modeled Residue Count: 298 
  • Deposited Residue Count: 301 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:
|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Keratinase KP2A [auth AAA]301Pseudomonas aeruginosaMutation(s): 0 
EC: 3.4.24
UniProt
Find proteins for E3ULB4 (Pseudomonas aeruginosa)
Explore E3ULB4 
Go to UniProtKB:  E3ULB4
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupE3ULB4
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free:  0.240 (Depositor), 0.240 (DCC) 
  • R-Value Work:  0.208 (Depositor), 0.208 (DCC) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 44.122α = 90
b = 51.26β = 90
c = 120.708γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
xia2data reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2021-02-10
    Type: Initial release
  • Version 1.1: 2021-03-03
    Changes: Database references
  • Version 1.2: 2024-01-31
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.3: 2024-10-16
    Changes: Structure summary